The COVID Moonshot, an open science initiative, has identified a promising compound for inhibiting the replication of the COVID-19 virus, according to Israel’s Weizmann Institute of Science (WIS). The detailed findings, published in the journal Science, highlight a noncovalent, nonpeptidic inhibitor scaffold with lead-like properties. This compound differs from current main protease inhibitors, showcasing a unique approach to hindering viral replication. The COVID Moonshot campaign, initiated in March 2020 as a non-profit collaboration of global researchers, aims to facilitate the development of affordable anti-COVID-19 drugs for low-income countries by allowing pharmaceutical companies to produce generic drugs without patents. The success of this open science framework emphasizes transparency, collaboration, and accessibility in research efforts.
Source – CGTN